anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses dihydroartemisinin mPEG-PLGA nano particles and a preparation method thereof. The invention provides a preparation method of dihydroartemisinin mPEG-PLGA nano particles, which is simple and quick to operate, and overcomes the defects of poor water solubility and low bioavailability of dihydroartemisinin. The tannic acid-iron ion metal-polyphenol network structure has low cytotoxicity, can be degraded in an acidic tumor microenvironment, and can participate in the redox reaction of Fe < 3+ > and Fe < 2+ > due to the reducibility of tannic acid. Increases the ferrous ion concentration in tumor cells, triggers Fenton reaction, and improves the iron death induction effect of the dihydroartemisinin. Experimental results show that the dihydroartemisinin nano-particles can obviously inhibit proliferation and migration of 4T1 tumor cells, and the IC50 is greatly lower than that of free dihydroartemisinin. The dihydroartemisinin nanoparticle has good inhibition effect on tumor cells and has application prospect of being developed into a good anti-tumor drug.
Patients in group A will receive a screw-retained implant crown. Following this first period of 16 weeks, the screw-retained implant crown will be replaced by a new intraorally cemented implant crown. Cement removal will be preformed according to best clinical procedure. These implant crowns will again be left for another period of 16 weeks and followed up for the harvesting of microbiological samples every 8 weeks. After the second 16-week the implant crowns will be removed to evaluate any excess cement. All patients will be fitted with the original screw-retained implant crown. Clinical parameters for inflammation and probing depths will be obtained after each 16 week-period.
Patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). In this pragmatic trial, treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
Antifreeze polypeptides, antifreeze compositions including the polypeptides, nucleotides encoding the antifreeze polypeptides, methods of making antifreeze compositions, and methods of inhibiting ice crystal growth are provided herein. The peptides are based on the primary sequence of collagen and include those having a molecular weight between about 500-7000 Da. The peptides preferably include cationic polypeptides. The methods of making antifreeze compositions include digesting collagen or gelatin into hydrolysates with peptides having molecular weights between about 500-7000 Da. The digestions are performed with proteases and/or non-enzymatic hydrolysis. The methods of inhibiting ice crystal growth include adding the antifreeze polypeptides or compositions described herein to a composition to be frozen. The methods may be used to inhibit ice crystal growth in frozen food products.
Infusion-related events are related to both the concentration and the rate of administration of vancomycin. Concentrations of no more than 5 mg/mL and rates of no more than 10 mg/min are recommended in adults (see also age-specific recommendations). In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used; use of such higher concentrations may increase the risk of infusion-related events. An infusion rate of 10 mg/min or less is associated with fewer infusion-related events (see ADVERSE REACTIONS). Infusion-related events may occur, however, at any rate or concentration.

The use of ADD-Vantage vials of vancomycin hydrochloride is indicated only when doses of 500 mg, 750 mg or 1 g are appropriate. Patient factors, such as renal function and age, are critical in calculating correct dosage regimens (see below). If doses of 500 mg, 750 mg or 1 g are determined to be inappropriate, conventional vials of vancomycin hydrochloride should be used. ADD-VANTAGE VIALS OF VANCOMYCIN HYDROCHLORIDE SHOULD NOT BE USED IN NEONATES, INFANTS, OR PEDIATRIC PATIENTS WHO REQUIRE DOSES OF LESS THAN 500 MG.
In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC after the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Each patient will undergo an assessment in the Aerobics Clinic and will receive a prescription for aerobic training based on the assessment findings. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
<P>PROBLEM TO BE SOLVED: To provide a skin care preparation for external use having excellent anti-inflammatory and antiallergic actions.  <P>SOLUTION: This preparation is obtained by mixing pyroligneous acid or bamboo pyroligneous acid with an extracted solution of Houttuynia cordata and dried leaves of Eriobotrya japonica as active ingredients. The skin care preparation for external use is obtained by mixing pyroligneous acid and the bamboo pyroligneous acid with the extracted solution of Houttuynia cordata and dried leaves of Eriobotrya japonica as active ingredients. The blending ratio of pyroligneous acid or bamboo pyroligneous acid is about 40 wt.%. The blending ratio of pyroligneous acid and bamboo pyroligneous acid is about 10-40 wt.%. The blending ratio of the extracted solution of Houttuynia cordata and dried leaves of Eriobotrya japonica is about 20-50 wt.%.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A system for selection of a medical provider (MP) by a requesting patient based on preferences for the MP includes a first model modeling the preferences of a plurality of patients for select MPs and trained on a first training data set comprised of patients and MPs. The patients in the first training data set have rated at least one of the MPs in the first data set by a predetermined set of patient determined preferences. A second model is provided for modeling the preferences of a plurality of MPs for select patients and trained on a second training data set comprised of MPs and patients. The MPs in the second training data set have rated at least one of the patients in the second data set by a predetermined set of MP determined preferences. An available MP data set is provided containing information representative of available MPs for selection thereof by the requesting patient. A controller controls the first and second models to select at least a portion of the available MPs in the available MP data set for input of the associated representative information to the first and second model MP inputs. A list generator generates a ranked list of available MPs from the output of the first model for the requesting patient. A combiner modifies the ranked list of available MPs by the output of the second model to output a modified ranked list.
PD-L1 negative patients will be given 3 mg/kg of Nivolumab plus 1 mg/kg of Ipilimumab I.V. each given over 30 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for a total of 2 cycles.
PROBLEM TO BE SOLVED: To obtain the subject detergent which shows excellent physical properties, e.g. spread on skin, viscosity and the like, along with the excellent detergency and is inexpensive and excellent in the preservative stability by including a gelatinized starch and a nonionic surfactant in a specific proportion. SOLUTION: The objective detergent is obtained by including (A) 0.1-10 wt.% of a gelatinized starch, (B) 0.5-50 wt.% of a nonionic surfactant and (C), when necessary, an aqueous viscosity-increasing agent, a moisturizer, a medicine, an antiseptic, a stabilizer to oxidation, a pearl agent, a washing base or a foaming agent. As the starch, tapioca starch or potato starch is preferably used. As the component B, e.g. an 8-20C monoglyceride (ethoxylate), an 8-20C higher fatty acid sugar ester or the like is preferably used. It is favorable that the component B is contained in an amount of 20 wt.% or more, preferably 30 wt.% or more or particularly 50 wt.% or more, based on the component A.
OBJECTIVE: Utilizing the combination of fluoroscopy and ultrasonography during Percutaneous Nephrolithotomy (PCNL) to minimize radiation exposure.
METHODS: In this randomized clinical trial, 118 patients with urinary stones who were candidates for PCNL surgery in the prone position were selected and divided into two groups (with an allocation ratio of 1:1). Cases were grouped according to whether ultrasonography was used for renal tract dilation and Amplatz sheath placement. The number of attempts to establish proper renal access, the time interval between access to the targeted calyx and nephroscope entrance, and the Clavien-Dindo score were collected.
RESULTS: The mean age of all patients was 46.12 ± 11.28 (45.6 ± 11.2 in the total fluoroscopy group and 46.5 ± 11.4 in the combined group) years (20-66). The intergroup differences in the baseline features were not significant. The mean duration of fluoroscopy time was significantly reduced in the combined guidance group (36.22 ± 10.73 vs. 23.05±8.94 seconds, (P-value = 0.001). Moreover, the difference in the distribution of Amplatz location on the nephroscopy time was meaningful (P-value = 0.016). However, intergroup differences in the number of attempts to successful puncture, length of hospitalization, recovery time, and postoperative complications, including gross hematuria duration, blood loss volume, pack cells requirement, pain score immediately and 6 hours after the surgery, and Clavien-Dindo score were not meaningful.
CONCLUSION: It can be concluded that the use of ultrasound with X-ray in prone PCNL compared to the use of X-rays alone can significantly reduce the duration of radiation without increasing the risk of intra-operative and postoperative detrimental events.
Previous studies have validated endoscopy, as an efficient tool for initial screening and in selected cases surveillance of families fulfilling the clinical criteria for hereditary diffuse gastric cancer (HDGC). The aim is to detect microscopic foci of in situ or intramucosal signet ring cell carcinoma (SRCC), which are characteristic of early HDGC. Currently, the recommended endoscopic protocol involves targeted biopsies of any suspicious lesion as well as a minimum of 30 mapping random biopsies specimens taken from all anatomic areas of the gastric mucosa, also known as Cambridge endoscopy protocol. However this is a time-consuming and tedious process, which significantly prolongs the duration of the procedure and might reduce patient tolerance. In order to save time two specimens can be taken during a single passage of the forceps ("double-bite" technique).

In order to evaluate the adequacy and utility of the "double-bite" technique, patients undergoing surveillance for HDGC, are randomized to the single-bite vs double-bite arm. Endoscopies are performed according to a standardized protocol. Briefly, a white-light high-resolution endoscope with 85 magnification and a maximal resolution of 7.9 mm (GIF-FQ260Z; Olympus, Tokyo, Japan) is used to examine all anatomic segments of the insufflated stomach. Any abnormalities on white-light endoscopy are recorded and assessed further by narrow-band imaging magnification with or without autofluorescence imaging. Targeted biopsy specimens are taken from identified lesions, and 5 random biopsy specimens are taken in each of the siz gastric anatomical areas (prepylorus, antrum, transitional zone, body, fundus, and cardia). The double-bite technique involves taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps. The single bite technique involves removing the forceps with its specimen after each individual biopsy. Time is recorded between the first and last random biopsy. Comfort score is reported after the procedure, according to the modified Gloucester scale. The investigators use Boston Single-Use Radial Jaw™ 4 biopsy forceps with a spike. Biopsy specimens are stained with hematoxylin and eosin and periodic acid-Schiff diastase and are assessed for size and presence of SRCC foci by an upper specialist GI pathologist, who have significant experience in SRCC identification. Any lesions are checked by a second pathologist within the Cambridge Pathology team before reporting. Both pathologists are blinded to study arm.
Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Dexmedetomidine. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 1mcg/kg over 10 minutes then 0.2 mcg/Kg/h and modified to a maximum of 0.7 mcg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four with a maximum.
Provided is a collagen structure characterized by: comprising collagen fibers of 1 to 5 µm in average diameter; and has a water content of 0 to 15 (w/w)% and a collagen density of 50 to 800 mg/cm 3 . After generating collagen fibers by neutralizing an acidic collagen solution, the resulting solution is subjected to filtration or the like to form crude collagen fibers having a collagen concentration of 12 to 50 (w/v)%. The thus obtained crude collagen fibers are molded into a prescribed shape and then dried, thereby the collagen structure can be produced. Since the collagen structure is produced using, as raw material, collagen fibers that are formed by association of collagen molecules, the collagen structure has excellent cell infiltration property. Further, since the collagen density of the collagen structure is equivalent to that of in vivo collagen tissue, the collagen structure exhibits excellent tissue regeneration capacity when filled into a defective part in vivo. Therefore, the collagen structure can be preferably used as an artificial material for regenerative medicine and the like.
The intervention builds on a previously unpublished face-to-face protocol for greek-speaking chronic pain sufferers (developed by Karekla \& Vasiliou, 2013) and has been simplified and modified to produce a self-help digital internet-based modality, namely the ALGEApp. ALGEApp consists of a total of 4 approximately one-hour sessions, which are structured to be completed by the users in sequence within a time frame of 2-8 weeks (depending on the rate of completion by each user). The intervention is guided, which implies that an animated character (an Avatar) guides the user throughout the whole duration of the intervention. ALGEApp contains experiential and audiovisual psycho-educational material based on ACT, adopted for the Greek-Cypriot culture.
We aimed to determine the clinical characteristics of patient self-inflicted lung injury (P-SILI)-associated pneumothorax/pneumomediastinum, to reveal its risk factors, and to assess its impact on severe COVID-19 cases. In total, 229 patients were included in this case-control study. They were randomly divided into either the case group or the control group as per the inclusion and exclusion criteria. The two groups were further analyzed to reveal the risk factors of spontaneous pneumothorax/pneumomediastinum (SP/P). Finally, risk factors for death were analyzed in the case group and the relationship between death and SP/P was also analyzed among all patients. The mean age of patients was 59.69 ± 17.01 years, most of them were male (74.2%), and 62.0% of them had comorbidities upon admission. A respiratory rate higher than 30 BPM was a risk factor for SP/P (OR 7.186, 95% CI 2.414-21.391, P < 0.001). Patients with delayed intubation due to early application of HFNC or NIV had a higher mortality rate when they developed SP/P (P < 0.05). Additionally, advanced age increased the risk of death (P < 0.05). Finally, SP/P may be a risk factor for death among patients with severe COVID-19 (OR 2.047). P-SILI occurs in severe COVID-19 with acute respiratory failure. It is necessary to identify the risk factors of P-SILI, the indicators of severe P-SILI, and the preventive measures.
The invention relates to a method for preparing a metformin hydrochloride controlled-release pellet preparation. A metformin hydrochloride controlled-release pellet is composed of a drug-contained pellet core and a controlled-release layer. The drug-contained pellet is composed of metformin hydrochloride, a filling agent and an adhesive. The controlled-release layer is composed of a controlled-release material and a pore-foaming agent. The metformin hydrochloride controlled-release pellet is mixed with pioglitazone hydrochloride controlled-release pellets to obtain the compounded metformin hydrochloride/pioglitazone hydrochloride controlled-release pellet preparation which achieves the ideal effect of regulating a blood sugar level, can reduce toxic and side effects of drugs, can achieve the effect of continuously and stably reducing the blood sugar level in the body, and facilitate improvement of the compliance of a patient. The compounded metformin hydrochloride controlled-release pellet preparation has high bioavailability and stable blood concentration. Clinical effects are effectively improved and a better dosage regimen and a better treatment effect are provided for domestic and overseas diabetics.
BACKGROUND: Alopecia, or hair loss, is an emerging global disease. Its etiopathogenesis includes nutritional deficiencies, oxidative stress, and deficiency of physiological factors. Around 2% of the general population has the probability of developing alopecia at any one period. Vitamin D and interleukin-6 (IL-6) have a major role in alopecia. The present goal of research is to investigate the role of vitamin D and IL-6 in the saliva of patients with non-scarring alopecia.
METHODOLOGY: The study involved 51 cases of non-scarring alopecia and 50 healthy controls with an age range between 18 and 40 years. A detailed history and clinical examination were done. Salivary vitamin D and IL-6 were determined to compare within the groups.
RESULTS: The average vitamin D level in cases (104.64 ± 46.95 pmol/L) was significantly lower as compared to controls (223 ± 12.03 pmol/L) (p < 0.001). Whereas the average amount of IL-6 was significantly higher (170.54 ± 63.68 ng/L) than the control group (56.38 ± 46.52 ng/L) (p < 0.001). No correlation of vitamin D level with IL-6 was detected in study subjects.
CONCLUSION: Vitamin D significantly influences the development of non-scarring alopecia. Patients with non-scarring alopecia had low amount of vitamin D indicate its role in etiology of hair loss. IL-6 may cause a collapse of the hair bulb, having a significant part in the pathogenesis of alopecia indicating chronic inflammatory or autoimmune condition. This research will aid in diagnosing scalp disease using salivary biomarkers and improve the treatment of alopecia.
The investigators are undertaking a prospective trial of patients with ITP in China. Zanubrutinib is administered as 80 mg po. qd for 6 weeks. Eltrombopag is given with 50 mg once daily for up to 6 weeks. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. This study assessed the efficacy and safety of eltrombopag plus zanubrutinib.
Patients in this group will receive Neuroscience-Based Pain Education (NPE) treatment in addition to the home exercise program. Training sessions are planned once a week for an average of 35-45 minutes and 8 sessions. NPE will be performed by a physiotherapist who has an internationally recognized certificate in this regard. Training sessions will be organized as one-on-one conversation sessions focusing on the neurophysiology of pain, and patients will be reinforced through PowerPoint presentations and visual pictures, templates, and metaphors.
The Trigonella species possess medicinal, nutraceutical and pharmaceutical properties due to the presence of many bioactive compounds. Its therapeutic effects are mostly valuable in medicine, cosmetics and the functional food industry. Correct genetic characterisation of plant material is needed to increase the potential of Trigonella species by breeding and conservation programs. The aim of this study was to develop a reliable marker system to support the morphological and phytochemical analysis in Trigonella taxonomic research, species identification and characterization as well as determination of the interspecific variation within this genus along with relationships between species. For this purpose, flow cytometry and SCoT molecular markers were combined. Flow cytometric analyses revealed that Trigonella species possess very small and small genomes. The range of genome sizes was from 1.10 to 5.76 pg/2C, with most species possessing very small genomes (< 2.8 pg/2C). In seeds of 14 species endopolyploid nuclei were detected. Flow cytometric analysis of genome size enabled quick identification of four out of 20 species, while combined with endopolyploidy detection in seeds, facilitated distinction of the next seven species. ScoT molecular markers helped to identify closely related species with similar genome size and cell cycle activity. Therefore, flow cytometry was proposed as the first-choice method for quick accession screening, while the more detailed genetic classification was obtained using SCoT molecular markers.
Should overdosage of tamsulosin hydrochloride capsules lead to hypotension [ ] support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then administration of intravenous fluids should be considered. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that tamsulosin hydrochloride is 94% to 99% protein bound; therefore, dialysis is unlikely to be of benefit.

  
see Warnings and Precautions ( ) and Adverse Reactions ( ) 5.16.1,
ONPATTRO must be filtered and diluted prior to intravenous infusion. The diluted solution for infusion should be prepared by a healthcare professional using aseptic technique as follows:

  * Remove ONPATTRO from the refrigerator and allow to warm to room temperature. Do not shake or vortex.
  * Inspect visually for particulate matter and discoloration. Do not use if discoloration or foreign particles are present. ONPATTRO is a white to off-white, opalescent, homogeneous solution. A white to off-white coating may be observed on the inner surface of the vial, typically at the liquid-headspace interface. Product quality is not impacted by presence of the white to off-white coating.
  * Calculate the required dose of ONPATTRO based on the recommended weight-based dosage [see Dosage and Administration (2.1)].
  * Withdraw the entire contents of one or more vials into a single sterile syringe.
  * Filter ONPATTRO through a sterile 0.45 micron polyethersulfone (PES) syringe filter into a sterile container.
  * Withdraw the required volume of filtered ONPATTRO from the sterile container using a sterile syringe. 
  * Dilute the required volume of filtered ONPATTRO into an infusion bag containing 0.9% Sodium Chloride Injection, USP for a total volume of 200 mL. Use infusion bags that are di(2-ethylhexyl)phthalate-free (DEHP-free).
  * Gently invert the bag to mix the solution. Do not shake. Do not mix or dilute with other drugs.
  * Discard any unused portion of ONPATTRO.
  * ONPATTRO does not contain preservatives. The diluted solution should be administered immediately after preparation. If not used immediately, store in the infusion bag at room temperature (up to 30°C [86°F]) for up to 16 hours (including infusion time). Do not freeze.